Mobile

This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therap...

Update Il y a 4 ans
Reference: EUCTR2014-001052-39

This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therapy

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Co-primary: • Compare progression-free survival (PFS) in patients treated with carfilzomib + filanesib and single-agent carfilzomib • Compare objective response rates (ORR) in patients with low serum alpha 1-acid glycoprotein (AAG) levels at Baseline treated with carfilzomib + filanesib and single-agent carfilzomib

Inclusion criteria

  • Multiple myeloma

Links